US EditionAtossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
Atossa's operating expenses rose 34% to $37.1 million driven by R&D and legal fees; FDA granted Rare Pediatric Disease and Orphan Drug designations for (Z)-endoxifen.
- On Wednesday, March 25, 2026, Atossa Therapeutics Inc released its quarterly and annual figures. This report offers an update on corporate developments and clinical milestones achieved by the company.
- Dr. Steven Quay, CEO, concluded, "We believe we are well-positioned to execute and advance our clinical programs toward key value-creating milestones." The company is developing -endoxifen for Duchenne Muscular Dystrophy and McCune-Albright Syndrome.
- Financial disclosures show a consolidated net loss of $10.4 million for the year ended December 31, 2025. Total operating expenses reached $37.1 million during this period as the company executed its clinical development strategy.
- Separately, COSCIENS Biopharma Inc filed an application on March 23, 2026, regarding insolvency proceedings for its German subsidiaries. This strategic decision follows the company's efforts to cease funding these international operations.
- MediPharm Labs Corp will release its financial results on Monday, March 30, 2026. Management expects to host a conference call to discuss these performance metrics with investors and the public.
38 Articles
38 Articles
Bennington Banner
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
SEATTLE, March 25, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announces its financial results for the fourth…
Waterloo Chronicle
MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results
TORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its full year and…
The Hamilton Spectator
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
TORONTO, ONTARIO, March 25, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”), a life science company focused on the development of natural, plant-based active ingredients, today reported its financial and operating results for…
Atossa Genetics (NASDAQ:ATOS) Issues Quarterly Earnings Results
Atossa Genetics (NASDAQ:ATOS – Get Free Report) announced its earnings results on Wednesday. The company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($0.29), FiscalAI reports. Atossa Genetics Trading Down 1.6% Shares of ATOS stock traded down $0.09 during trading hours on Wednesday, reaching $5.42. 129,381 shares […]
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
